News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
CRISPR 2.0, the Next Generation
June 21, 2024
Aspen Ideas: Health
CRISPR 2.0, the Next Generation
June 21, 2024
All Stories
News
Building a biotech in a downturn: 3 lessons from VCs and startup CEOs
November 3, 2022
Biopharma Dive
Read Now
Press Release
Building a biotech in a downturn: 3 lessons from VCs and startup CEOs
November 3, 2022
Biopharma Dive
Read Now
News
Deals In Depth: September 2022
October 18, 2022
In Vivo
Read Now
Press Release
Deals In Depth: September 2022
October 18, 2022
In Vivo
Read Now
News
Scribe Therapeutics to Participate in Upcoming Investor Conferences
September 29, 2022
Read Now
Press Release
Scribe Therapeutics to Participate in Upcoming Investor Conferences
September 29, 2022
Read Now
News
Scribe and Sanofi partner to develop cell therapies for cancer
September 28, 2022
Pharmaceutical Technology
Read Now
Press Release
Scribe and Sanofi partner to develop cell therapies for cancer
September 28, 2022
Pharmaceutical Technology
Read Now
News
Follow the Money
September 28, 2022
Bio-IT World
Read Now
Press Release
Follow the Money
September 28, 2022
Bio-IT World
Read Now
News
Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer
September 27, 2022
Read Now
Press Release
Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer
September 27, 2022
Read Now